According to the current analysis
of Reports and Data, the global Hemophilia
market was valued at USD 11.10 Billion in 2018 and is expected to
reach USD 16.84 Billion by the year 2026, at a CAGR of 5.4 percent. Hemophilia
is a rare genetic disorder in which blood doesn't clot normally because it lacks
sufficient blood-clotting proteins known as clotting factors. Among the types
of disorders, type A is anticipated to be multiple times more predominant than
type B. The global market for hemophilia drugs is growing significantly,
owing to the increasing number of hemophilic patients globally. Hemophilia
medications are turning out to be one of the essential medicinal products to
confine the loss of blood as there is no exact treatment accessible to treat
this disorder. Strategies such as geographical expansion by the key market
players and new product development are expected to have the most impact on the
Hemophilia market. Rising prevalence of the disorder, a significant focus
of key market players on the development of gene therapy mechanism, increasing
awareness about the disorder, and favorable regulatory scenario, are some of
the key factors that support the market growth in the industry.
However, lack of availability of
medicine and high cost of treatment are the factors that limit the market
growth over the globe during 2019-2026.
To identify the key trends in
the industry, click on the link below:
Further key findings from
the report suggest
- Launch of products for hemophilia treatment is
expected to support the market growth during the coming years. For
instance, in May 2018 FDA approved Roche’s Hemlibra for treatment of
hemophilia with or without inhibitors.
- North America dominates the regional hemophilia
market and held around 48% market share in 2018.
- Hemophilia B is projected to be the fastest growing
segment at a CAGR of 5.7%. However, low availability of treatment for the
segment is a major challenge for the market growth for this segment.
- Asia Pacific is expected to show a high growth rate
in the hemophilic market and will grow at a CAGR of 6%
- Recombinant coagulation factor concentrate and plasma
coagulation factor concentrate are the common options to treat hemophilia
and are expected to take up an important position in the global hemophilia
market owing to increased prevalence of the von Willebrand Disease.
- On-demand treatment segment is expected to grow at a
CAGR of 5.6%.
- Treatment for hemophilia is in the clinical pipeline
stage. And the multiple treatments that are underway are expected to
significantly improve the quality of life of patients suffering from
hemophilia.
- Availability of treatment and lack of awareness about
hemophilia is likely to hinder the market growth during the forecast
period.
- Key participants include Shire (Takeda), Bayer Healthcare, CSL Behring, Novo Nordisk, Sanofi, Pfizer Inc., among others
No comments:
Post a Comment